Avidity Biosciences (RNA) Operating Leases (2019 - 2025)
Historic Operating Leases for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $50.0 million.
- Avidity Biosciences' Operating Leases rose 121593.36% to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.0 million, marking a year-over-year increase of 121593.36%. This contributed to the annual value of $3.0 million for FY2024, which is 5240.62% down from last year.
- According to the latest figures from Q3 2025, Avidity Biosciences' Operating Leases is $50.0 million, which was up 121593.36% from $1.2 million recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' Operating Leases registered a high of $50.0 million during Q3 2025, and its lowest value of $877000.0 during Q3 2021.
- In the last 5 years, Avidity Biosciences' Operating Leases had a median value of $6.2 million in 2023 and averaged $7.5 million.
- Within the past 5 years, the most significant YoY rise in Avidity Biosciences' Operating Leases was 121593.36% (2025), while the steepest drop was 7379.25% (2025).
- Quarter analysis of 5 years shows Avidity Biosciences' Operating Leases stood at $10.0 million in 2021, then fell by 23.88% to $7.6 million in 2022, then dropped by 18.06% to $6.2 million in 2023, then plummeted by 52.41% to $3.0 million in 2024, then skyrocketed by 1589.75% to $50.0 million in 2025.
- Its Operating Leases stands at $50.0 million for Q3 2025, versus $1.2 million for Q2 2025 and $2.1 million for Q1 2025.